Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.53 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628705 | 0.88 | HTT (0.68) | HTTSMN1; SMN2F2RL1CTBP2ALDH1A1 | |
| SCHEMBL7153605 | 0.82 | HTT (0.61) | HTTSMN1; SMN2F2RL1CTBP2ALDH1A1 | |
| SCHEMBL3175977 | 0.82 | HTT (0.61) | HTTSMN1; SMN2F2RL1CTBP2ALDH1A1 | |
| SCHEMBL8308364 | 0.81 | LMNA (0.50) | SMN1; SMN2ALDH1A1CYP3A4TP53KDM4E | |
| SCHEMBL10492444 | 0.81 | NQO1 (0.50) | SMN1; SMN2ALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL9216095 | 0.81 | F2RL1 (0.74) | GSK3BSMN1; SMN2F2RL1ALDH1A1CYP3A4 | |
| SCHEMBL11225811 | 0.81 | HTT (0.59) | HTTSMN1; SMN2F2RL1CTBP2ALDH1A1 | |
| SCHEMBL3006056 | 0.81 | HTT (0.59) | HTTSMN1; SMN2F2RL1CTBP2ALDH1A1 | |
| SCHEMBL8867104 | 0.81 | HTT (0.59) | HTTSMN1; SMN2F2RL1CTBP2ALDH1A1 | |
| SCHEMBL4032340 | 0.81 | NPC1 (0.66) | HTTSMN1; SMN2CTBP2ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051296-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-02-13 | — | — | US | disclosed |
| US-12103917-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-10-01 | — | — | US | disclosed |
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-09-30 | — | — | US | disclosed |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-06-08 | — | — | US | disclosed |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Bumham Prebys Medical Discovery Imstitute (US) | 2018-08-09 | — | — | US | disclosed |
| WO-2017019772-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2017-02-02 | — | — | WO | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011038293-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-7645903-B2 | immunoglobulins; affinity chromatography | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2010-01-12 | — | — | US | disclosed |
| US-20090138208-A1 | IMMUNOGLOBULIN G BINDING POCKET | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20060014735-A1 | Use of urea variants as affinity ligands | CYTIVA BIOPROCESS R&D AB (SE) | 2006-01-19 | — | — | US | disclosed |
| WO-2004039843-A1 | IMMUNOGLOBULIN G BINDING POCKET | AMERSHAM BIOSCIENCES AB (SE) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004039765-A1 | USE OF UREA VARIANTS AS AFFINITY LIGANDS | AMERSHAM BIOSCIENCES AB (SE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051296-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | HTT 3617/4885GSK3B 444/4885SMN1; SMN2 205/4885 |
| US-20060014735-A1 | Use of urea variants as affinity ligands | IGLV6-57, FCGR2A, FCGR3B | HTT 3281/4885GSK3B 3027/4885SMN1; SMN2 4731/4885 |
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | HTT 3617/4885GSK3B 444/4885SMN1; SMN2 205/4885 |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | HTT 1023/4885GSK3B 203/4885SMN1; SMN2 2434/4885 |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | HTT 3617/4885GSK3B 444/4885SMN1; SMN2 205/4885 |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | HTT 4717/4885GSK3B 2109/4885SMN1; SMN2 3157/4885 |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | MYC, MYCBP, MLYCD | HTT 3617/4885GSK3B 444/4885SMN1; SMN2 205/4885 |
| US-12103917-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | MYC, MYCBP, MLYCD | HTT 3617/4885GSK3B 444/4885SMN1; SMN2 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.